L-NIBC-Bound Au18 Gold Cluster for Therapeutic Precision
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The complexity of gold clusters, with varying numbers of gold atoms and ligands, makes it challenging to identify specific gold cluster molecules with consistent therapeutic effects, hindering their druggability and application in treating diseases such as multiple sclerosis, Alzheimer's disease, liver cirrhosis, diabetes, Parkinson's disease, and glaucoma.
Innovation Solution
The development of an L-N-isobutyryl cysteine (L-NIBC)-bound gold cluster molecule, Au18(L-NIBC)14, which is specifically formulated and purified to achieve a chromatographic content of at least 7% in compositions used for treating various diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If gold clusters with varying numbers of gold atoms and ligands are used, then the versatility and adaptability of the material is improved, but the manufacturing precision and reliability of specific therapeutic molecules deteriorate
Solution Approach 1:
The patent segments the complex gold cluster system into specific molecular entities with defined compositions (e.g., Au25(L-NIBC)18, Au102(L-NIBC)66). By isolating and characterizing individual gold cluster molecules with precise atom counts and ligand configurations, the invention transforms the heterogeneous mixture into discrete, well-defined therapeutic agents, thereby resolving the contradiction between material versatility and manufacturing precision.
2Adaptability or versatility
If the number of gold atoms and ligands varies in gold clusters, then the adaptability for different diseases is improved, but the difficulty of detecting and measuring specific molecules increases
Solution Approach 1:
The patent utilizes the distinct optical absorption characteristics of different gold cluster molecules as identification markers. Each specific gold cluster composition (e.g., Au25, Au102) exhibits unique absorption spectra that serve as fingerprint signatures. This optical property enables straightforward detection and quantification of specific molecules in complex mixtures through UV-Vis spectroscopy, thereby reducing the difficulty of detection while maintaining adaptability across disease applications.
3Manufacturing precision
If gold clusters with specific numbers of gold atoms and ligands are targeted, then the manufacturing precision is improved, but the device complexity and purification difficulty increase
Solution Approach 1:
The patent employs extraction techniques to isolate specific gold cluster molecules from crude reaction mixtures. By using size-exclusion chromatography and other separation methods, the invention extracts target molecules (e.g., Au25(L-NIBC)18) from complex preparations containing multiple gold cluster species. This extraction approach achieves high manufacturing precision while managing purification complexity through systematic separation strategies.
Data Source
AI summary
L-N-isobutyryl cysteine (L-NIBC)-bound gold cluster Au18(L-NIBC)14, its use for treating multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, diabetes, Parkinson's disease (PD) or glaucoma, and the use of it for manufacturing a medicament for treatment of multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, diabetes, Parkinson's disease (PD) or glaucoma. Composition and methods for treating multiple sclerosis, Alzheimer's disease (AD), liver cirrhosis, diabetes, Parkinson's disease (PD) or glaucoma.